In addition to the presenter, following authors who may have helped with the content writing, review, or approval declare no conflict of interest.
In this talk, we will discuss the following topics:
Johnson and Johnson's vaccine is different from others because it is a single-shot vaccine.
Phase III trial interim results of the J&J vaccines showing
a) 100% protection from COVID related deaths
b) 85% protection from the severe COVID disease
c) 66% overall efficacy
Countries in which the vaccine trial is conducted
The reason for lesser efficacy in South Africa
Side effects are similar to a placebo that is not too bad
Mobeen Syed M.D, MS Graduated from King Edward Medical University. Entrepreneur, Medical Educator, CEO and founder of Drbeen corp.